Stelios Papadopoulos - Net Worth and Insider Trading

Stelios Papadopoulos Net Worth

The estimated net worth of Stelios Papadopoulos is at least $34 Million dollars as of 2024-03-19. Stelios Papadopoulos is the Director of Exelixis Inc and owns about 1,220,036 shares of Exelixis Inc (EXEL) stock worth over $28 Million. Stelios Papadopoulos is the Director of Biogen Inc and owns about 26,580 shares of Biogen Inc (BIIB) stock worth over $6 Million. Stelios Papadopoulos is also the Director of Regulus Therapeutics Inc and owns about 118,987 shares of Regulus Therapeutics Inc (RGLS) stock worth over $280,809. Details can be seen in Stelios Papadopoulos's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Stelios Papadopoulos has not made any transactions after 2022-02-22 and currently still holds the listed stock(s).

Transaction Summary of Stelios Papadopoulos

To

Stelios Papadopoulos Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Stelios Papadopoulos owns 7 companies in total, including Regulus Therapeutics Inc () , Biogen Inc () , and Exelixis Inc () among others .

Click here to see the complete history of Stelios Papadopoulos’s form 4 insider trades.

Insider Ownership Summary of Stelios Papadopoulos

Ticker Comapny Transaction Date Type of Owner
Regulus Therapeutics Inc 2019-05-07 director
Biogen Inc 2015-07-27 director
Exelixis Inc 2022-02-22 director
BG Medicine Inc 2015-11-18 director
Genvec Inc 2006-06-22 director
Eucrates Biomedical Acquisition Corp 2020-10-23 director & 10 percent owner
Eucrates Biomedical Acquisition Corp 2020-10-23 director & 10 percent owner

Stelios Papadopoulos Latest Holdings Summary

Stelios Papadopoulos currently owns a total of 3 stocks. Among these stocks, Stelios Papadopoulos owns 1,220,036 shares of Exelixis Inc (EXEL) as of February 22, 2022, with a value of $28 Million and a weighting of 82.22%. Stelios Papadopoulos owns 26,580 shares of Biogen Inc (BIIB) as of July 27, 2015, with a value of $6 Million and a weighting of 16.96%. Stelios Papadopoulos also owns 118,987 shares of Regulus Therapeutics Inc (RGLS) as of May 7, 2019, with a value of $280,809 and a weighting of 0.82%.

Latest Holdings of Stelios Papadopoulos

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
EXEL Exelixis Inc 2022-02-22 1,220,036 23.17 28,268,234
BIIB Biogen Inc 2015-07-27 26,580 219.40 5,831,652
RGLS Regulus Therapeutics Inc 2019-05-07 118,987 2.36 280,809

Holding Weightings of Stelios Papadopoulos


Stelios Papadopoulos Form 4 Trading Tracker

According to the SEC Form 4 filings, Stelios Papadopoulos has made a total of 3 transactions in Exelixis Inc (EXEL) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Exelixis Inc is the sale of 84,515 shares on February 22, 2022, which brought Stelios Papadopoulos around $2 Million.

According to the SEC Form 4 filings, Stelios Papadopoulos has made a total of 0 transactions in Biogen Inc (BIIB) over the past 5 years. The most-recent trade in Biogen Inc is the acquisition of 10,000 shares on July 27, 2015, which cost Stelios Papadopoulos around $3 Million.

According to the SEC Form 4 filings, Stelios Papadopoulos has made a total of 1 transactions in Regulus Therapeutics Inc (RGLS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Regulus Therapeutics Inc is the acquisition of 37,037 shares on May 7, 2019, which cost Stelios Papadopoulos around $400,000.

Insider Trading History of Stelios Papadopoulos

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Stelios Papadopoulos Trading Performance

GuruFocus tracks the stock performance after each of Stelios Papadopoulos's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Stelios Papadopoulos is 3.37%. GuruFocus also compares Stelios Papadopoulos's trading performance to market benchmark return within the same time period. The performance of stocks bought by Stelios Papadopoulos within 3 months outperforms 3 times out of 9 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Stelios Papadopoulos's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Stelios Papadopoulos

Average Relative Return

-9.5%

Average relative return per transaction

Outperforming Transactions

22%

2 out of 9 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) -2.21 3.37 33.85 -9.5 -15.88 -24.16
Relative Return to S&P 500(%) -2.87 -0.49 25.43 -23.63 -31.07 -38.32

Stelios Papadopoulos Ownership Network

Ownership Network List of Stelios Papadopoulos

No Data

Ownership Network Relation of Stelios Papadopoulos


Stelios Papadopoulos Owned Company Details

What does Regulus Therapeutics Inc do?

Who are the key executives at Regulus Therapeutics Inc?

Stelios Papadopoulos is the director of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Sr. VP & General Counsel Christopher Ray Aker , Chief Operating Officer Joseph P Hagan , and Chief Financial Officer Crispina Calsada .

Regulus Therapeutics Inc () Insider Trades Summary

Over the past 18 months, Stelios Papadopoulos made no insider transaction in Regulus Therapeutics Inc (). Other recent insider transactions involving Regulus Therapeutics Inc () include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Crispina Calsada , and a net sale of 5,468 shares made by Christopher Ray Aker .

In summary, during the past 3 months, insiders sold 25,516 shares of Regulus Therapeutics Inc () in total and bought 0 shares, with a net sale of 25,516 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 25,516 shares.

Regulus Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Regulus Therapeutics Inc Insider Transactions

No Available Data

Stelios Papadopoulos Mailing Address

Above is the net worth, insider trading, and ownership report for Stelios Papadopoulos. You might contact Stelios Papadopoulos via mailing address: 3 Somerset Drive South, Great Neck Ny 11020.

Discussions on Stelios Papadopoulos

No discussions yet.